A concerning trend has emerged in the use of popular weight-loss drugs like Wegovy and Zepbound, which have been found to trigger or worsen eating disorders in some patients. These drugs, also known as GLP-1 drugs, work by curbing hunger and regulating blood sugar levels but have been linked to the development of eating disorders such as anorexia nervosa. Doctors are increasingly seeing patients who have spiraled into restrictive eating habits after starting these medications, which can lead to serious health consequences.
Misuse of weight-loss drugs is not new, but the phenomenon with GLP-1 drugs is unprecedented. Experts are calling for more awareness and screening for eating disorders in individuals prescribed these medications for weight loss. Studies have shown an increased risk of abuse among patients taking semaglutide, the active ingredient in these drugs. Some patients, even when taking the medications as prescribed, have developed eating disorders like anorexia or binge eating disorder.
While some doctors report positive outcomes in using GLP-1 drugs to treat binge eating disorder, others are concerned that the medications may worsen symptoms in some patients. The lack of large, rigorous studies on the use of these drugs in treating eating disorders is a significant gap in understanding the potential risks.
There are also safety concerns for children and adolescents prescribed these medications, as the risk of developing eating disorders may be even higher in this population. Experts recommend thorough screening for eating disorders and close monitoring of patients’ weight to prevent potential harm from the use of GLP-1 drugs. It is essential for healthcare providers to educate patients on these risks and consider mental health support in conjunction with obesity treatment.
Photo credit
www.nbcnews.com